Eisai Asks U.S. Court Of Appeals To Set Deadline For DEA Scheduling Of Its Epilepsy Drug Fycompa
This article was originally published in PharmAsia News
Eisai says the U.S. Drug Enforcement Administration scheduling delay – 10 months after U.S. FDA approval and seven months after the U.S. Department of Health and Human Services submitted a scheduling recommendation – is “unreasonable and egregious.” Court filing follows citizen petition to FDA.
You may also be interested in...
Eisai citizen petition requests Belviq and Fycompa approval dates coincide with final DEA scheduling; Pozen advocates exclusivity for new combinations of previously approved molecules.
Eisai’s Fycompa becomes only the second drug with a new mechanism of action approved by FDA for epilepsy in the last decade.
Plaintiff Peter Lurie, former US FDA associate commissioner, expects results of hundreds of clinical trials of approved drugs will become available under ruling against HHS; co-plaintiff sought eteplirsen study data.